Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Jul 2006

Tokumo Masaki, Toyooka Shinichi, Ichihara Shuji, Ohashi Kadoaki, Tsukuda Kazunori, Ichimura Kouichi, Tabata Masahiro, Kiura Katsuyuki, Aoe Motoi, Sano Yoshifumi, Date Hiroshi, Shimizu Nobuyoshi

Abstract excerpt

Mutations of the epidermal growth factor receptor (EGFR) gene have been reported in non-small-cell lung cancer (NSCLC), especially in patients with adenocarcinoma and never smokers. Some common somatic mutations in EGFR, including deletion mutations in exon 19 and leucine-to-arginine substitution...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Gene Dosage

Share to In Situ Hybridization, Fluorescence

Share to Lung Neoplasms

Share to Quinazolines

Source

Identifiers

PMID: 16730855
DOI: 10.1016/j.lungcan.2006.04.008

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16730855-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.PMID 16730855Read ↗

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung CancerSemantic proximity Read ↗

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.Semantic proximity Read ↗

Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.Semantic proximity Read ↗

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsSemantic proximity Read ↗

Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung CancerSemantic proximity Read ↗

Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on PrognosisSemantic proximity Read ↗

[Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer].Semantic proximity Read ↗

High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.Semantic proximity Read ↗

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.